Yaupon Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Yaupon Therapeutics's estimated annual revenue is currently $1.6M per year.
- Yaupon Therapeutics's estimated revenue per employee is $155,000
Employee Data
- Yaupon Therapeutics has 10 Employees.
- Yaupon Therapeutics grew their employee count by -9% last year.
Yaupon Therapeutics's People
| Name | Title | Email/Phone |
|---|
Yaupon Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $1.4M | 9 | -10% | N/A | N/A |
#2 | $7.1M | 46 | 77% | N/A | N/A |
#3 | $14.4M | 93 | 27% | N/A | N/A |
#4 | $0.9M | 6 | 0% | N/A | N/A |
#5 | $1.6M | 10 | 43% | N/A | N/A |
#6 | $11.5M | 74 | 6% | N/A | N/A |
#7 | $0.9M | 11 | 22% | N/A | N/A |
#8 | $3.7M | 24 | -8% | N/A | N/A |
#9 | $2M | 13 | 18% | N/A | N/A |
#10 | $9.3M | 60 | 2% | N/A | N/A |
What Is Yaupon Therapeutics?
Yaupon Therapeutics is a privately-held specialty pharmaceutical company that develops small molecule pharmaceuticals licensed from under-served academic laboratories. The Company’s lead product candidate, Clearazide™, a proprietary topical formulation of nitrogen mustard (NM), is being evaluated in a pivotal Phase II/III trial under a Special Protocol Assessment (SPA) with the FDA for the treatment of early-stage cutaneous T-cell lymphoma – mycosis fungoides (CTCL-MF). The FDA has granted Clearazide™ fast-track designation and orphan drug status.
keywords:N/A
N/A
Total Funding
10
Number of Employees
$1.6M
Revenue (est)
-9%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Radnor
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1.5M | 12 | 9% | N/A |
#2 | $2.6M | 17 | 6% | N/A |
#3 | $1.5M | 17 | -29% | N/A |
#4 | $1.7M | 23 | -32% | $17.2M |
#5 | $2.6M | 25 | -22% | $4M |